Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 4/20 | 0.36 |
| ▸ | THRA | P10827 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | CCR2 | P41597 | 1/20 | 0.34 |
| ▸ | FKBP1A | P62942 | 5/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.30 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21186856 | 1.00 | RIPK1 (0.36) | RIPK1THRATHRBHSD11B1CCR2 | |
| SCHEMBL19223961 | 1.00 | RIPK1 (0.36) | RIPK1THRATHRBHSD11B1CCR2 | |
| SCHEMBL21703733 | 0.93 | RIPK1 (0.33) | RIPK1THRATHRBHSD11B1CCR2 | |
| SCHEMBL19367986 | 0.91 | SMN1; SMN2 (0.44) | RIPK1HSD11B1CCR2FKBP1ASMN1; SMN2 | |
| SCHEMBL13899557 | 0.89 | SMN1; SMN2 (0.42) | HSD11B1CCR2FKBP1ASMN1; SMN2HSD17B10 | |
| SCHEMBL19772908 | 0.88 | THRA (0.53) | RIPK1THRATHRBPOLB | |
| SCHEMBL19215805 | 0.86 | SMN1; SMN2 (0.44) | FKBP1ASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL13353976 | 0.84 | SMN1; SMN2 (0.44) | CCR2SMN1; SMN2HSD17B10POLBHTT | |
| SCHEMBL6141316 | 0.82 | THRA (0.36) | THRATHRBHSD11B1CCR2SMN1; SMN2 | |
| SCHEMBL12473297 | 0.82 | LMNA (0.35) | RIPK1FKBP1ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689430-B2 | Insulin receptor partial agonists | MERCK SHARP & DOHME CORP. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190177393-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177393-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | RIPK1 617/4885THRA 37/4885THRB 23/4885 |
| US-10689430-B2 | Insulin receptor partial agonists | INSR, GPR119, IRS1 | RIPK1 617/4885THRA 37/4885THRB 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.